-
A new-generation pulse oximeter with improved signal-extraction technology had less malfunctioning time than a conventional pulse oximeter placed on the same hand in postoperative cardiac surgery patients and was associated with fewer arterial blood gases and faster FIO2 reduction.
-
-
After years of legal wrangling, the FDA has approved loratadine (Claritin, Schering-Plough) as an over-the-counter (OTC) product for the treatment of seasonal rhinitis.
-
Fibrates and statins are associated with a 42-fold and 8-fold increased risk of myopathy, respectively, compared to normal controls, but the incidence remains low, at 6 per 100,000 and 1 per 100,000, respectively.
-
Considerable concern exists among clinicians regarding the risk-benefit ratio of long-term anticoagulation compared to antiplatelet treatment. In order to compare the risk of vascular events and bleeding complications in patients with AF, van Walraven and associates analyzed data from 6 randomized clinical trials.
-
-
Three recent studies have provided epidemiologic data that increased intake of antioxidants may be associated with a reduced risk of developing AD.
-
In this thoughtful, well-balanced review, Clarke and Guttman review the evidence for using new dopamine agonists to treat patients with early PD.
-
The results of 3 recent investigations suggest that immunotherapy still has the potential to become a treatment for AD but that the road to its successful development is likely to be a long one.
-
Aripiprazole (Abilify), a new drug for schizophrenia, received FDA approval November 15; on November 14, Neurocrine Biosciences Inc. announced positive results from its first phase III clinical trial with indiplon-IR achieving primary and secondary end points of sleep initiation.
